<html xmlns="http://www.w3.org/1999/xhtml"><body><table class="table"><caption /><tr><th class="cell">Variable </th><th class="cell">All patients </th><th class="cell">Placebo group </th></tr><tr><td class="cell">n treated</td><td class="cell">86</td><td class="cell">43</td></tr><tr><td class="cell">Age (y)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Mean (SD)</td><td class="cell">62.4 (8.7)</td><td class="cell">62.7 (9.1)</td></tr><tr><td class="cell">Range</td><td class="cell">37–79</td><td class="cell">43–79</td></tr><tr><td class="cell">Sex, n (%)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Male</td><td class="cell">57 (66)</td><td class="cell">32 (74)</td></tr><tr><td class="cell">Female</td><td class="cell">29 (34)</td><td class="cell">11 (26)</td></tr><tr><td class="cell">Race, n (%)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">White</td><td class="cell">83 (97)</td><td class="cell">42 (98)</td></tr><tr><td class="cell">Asian</td><td class="cell">2 (2)</td><td class="cell">1 (2)</td></tr><tr><td class="cell">Other</td><td class="cell">1 (1)</td><td class="cell">0</td></tr><tr><td class="cell">Country, n (%)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">US</td><td class="cell">64 (74)</td><td class="cell">32 (74)</td></tr><tr><td class="cell">Italy</td><td class="cell">10 (12)</td><td class="cell">5 (12)</td></tr><tr><td class="cell">Serbia</td><td class="cell">8 (9)</td><td class="cell">4 (9)</td></tr><tr><td class="cell">Great Britain</td><td class="cell">4 (5)</td><td class="cell">2 (5)</td></tr><tr><td class="cell">Modified H&amp;Y stage , n (%)^{a}</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">1.5</td><td class="cell">3 (4)</td><td class="cell">2 (5)</td></tr><tr><td class="cell">2</td><td class="cell">50 (58)</td><td class="cell">24 (56)</td></tr><tr><td class="cell">2.5</td><td class="cell">20 (23)</td><td class="cell">11 (26)</td></tr><tr><td class="cell">3</td><td class="cell">13 (15)</td><td class="cell">6 (14)</td></tr><tr><td class="cell">UPDRS Part III score, mean (SD)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">OFF state</td><td class="cell">35.8 (12.0)</td><td class="cell">36.2 (12.1)</td></tr><tr><td class="cell">ON state</td><td class="cell">17.5 (9.0)</td><td class="cell">18.9 (9.8)</td></tr><tr><td class="cell">Time since PD diagnosis (mon)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Mean (SD)</td><td class="cell">113 (47)</td><td class="cell">117 (48)</td></tr><tr><td class="cell">Range</td><td class="cell">38–255</td><td class="cell">41–255</td></tr><tr><td class="cell">Time since emergence of fluctuations (mon)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Mean (SD)</td><td class="cell">51 (43)</td><td class="cell">46 (40)</td></tr><tr><td class="cell">Range</td><td class="cell">0–254</td><td class="cell">0–150</td></tr><tr><td class="cell">OFF time (h/d)^{b}</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Mean (SD)</td><td class="cell">5.7 (1.8)</td><td class="cell">5.8 (1.5)</td></tr><tr><td class="cell">Range</td><td class="cell">2.6–10.3</td><td class="cell">2.6–9.2</td></tr><tr><td class="cell">Number of daily OFF episodes ^{c}</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Mean (SD)</td><td class="cell">3.6 (1.1)</td><td class="cell">3.7 (1.0)</td></tr><tr><td class="cell">Range</td><td class="cell">1.0–7.0</td><td class="cell">1.7–6.0</td></tr><tr><td class="cell">Duration of LD treatment (mon)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Mean (SD)</td><td class="cell">93 (46)^{d}</td><td class="cell">95 (48)^{e}</td></tr><tr><td class="cell">Range</td><td class="cell">15–254^{d}</td><td class="cell">15–243^{e}</td></tr><tr><td class="cell">Number of daily LD doses</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Mean (SD)</td><td class="cell">5.9 (1.9)</td><td class="cell">6.1 (2.2)</td></tr><tr><td class="cell">Range</td><td class="cell">4–15</td><td class="cell">4–15</td></tr><tr><td class="cell">LD daily dosage (mg/d)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Mean (SD)</td><td class="cell">770 (306)</td><td class="cell">853 (315)</td></tr><tr><td class="cell">Range</td><td class="cell">250–1800</td><td class="cell">400–1700</td></tr><tr><td class="cell">Other oral PD medications, n (%)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Dopamine agonists</td><td class="cell">57 (66%)</td><td class="cell">26 (61%)</td></tr><tr><td class="cell">MAO-B inhibitors</td><td class="cell">37 (43%)</td><td class="cell">14 (33%)</td></tr><tr><td class="cell">Adamantane derivatives</td><td class="cell">29 (34%)</td><td class="cell">13 (30%)</td></tr><tr><td class="cell">COMT inhibitors</td><td class="cell">9 (11%)</td><td class="cell">5 (12%)</td></tr></table></body></html>